Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.71−0.32 (-7.94%)
Close on Nov 13, 2026Market cap $154.33MP/E 1.1Yield 6.74%
Oramed Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Oramed Pharmaceuticals's ebitda for the twelve months ending May 31, 2015 was -$15.37M. For fiscal 2014 it was -$5.90M, down 236.9% from the year before.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2014 | Aug 31, 2014 | -$5.90M | -236.9% |
| FY2013 | Aug 31, 2013 | $4.31M | – |
| FY2012 | Aug 31, 2012 | -$2.87M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2016CQ2 2016 | May 31, 2016 | $2.11M | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | -$1.91M | – |
| Q1 FY2016CQ4 2015 | Nov 30, 2015 | $2.45M | – |
| Q3 FY2015CQ2 2015 | May 31, 2015 | -$1.63M | – |
See a number that looks wrong?